Business
Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session
Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Brea...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\n Nov. 17, 2010 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nA second AHA presentation includes mouse model data showing plaque\n reduction. \n\n\nTSX Exchange Symbol: RVX\n\n\nCHICAGO, Nov. 17 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) \n announces its top line results of the ASSERT Phase 2 clinical trial\n which will be highlighted at the prestigious American Heart Association\n Scientific Sessions 2010 Late Breaking Clinical Trial session, by\n principal investigator Dr. Stephen Nicholls of the Cleveland Clinic.\n The top line ASSERT trial data was designed to answer questions about\n how to best proceed with future trial designs for Resverlogix' lead\n oral small molecule drug RVX-208.\n\n\nThe ASSERT trial data demonstrated that the three key biomarkers in the\n reverse cholesterol transport (RCT) process showed dose dependant and\n consistent improvement. The trial showed dose dependent increases in\n ApoA-l, statistically significant increases in HDL cholesterol\n including alpha1 particles or functional HDL, and highly statistically\n significant increases in large HDL particles. RCT is a pathway by which\n accumulated cholesterol is transported from the arterial wall to the\n liver for excretion, thus reducing and/or preventing atherosclerosis.\n\n\nIn the high dose, ApoA-I achieved a 5.6% increase with a statistical\n value of p=0.06. The overall ApoA-I biomarker showed a dose trending\n statistical significance of p=0.035. Data presented ...